Viking Therapeutics: Still Cheap, But Watch Double Top

Viking Therapeutics is advancing its GLP-1 weight-loss pipeline, with Phase 3 trials progressing and oral formulation development accelerating. The consensus analyst price targets average $92.58, suggesting substantial upside. Recent biotech sector M&A highlights VKTX’s potential valuation in a rapidly expanding GLP-1 market. The stock valuation remains attractive, with consensus 2030 revenue estimates of $1.3 billion and market share estimates supporting a much larger portion of a potential $190 billion market in 2035. The GLP-1 sector has seen less attention over the last few months with the stock market obsessed with AI, but Viking Therapeutics, Inc. (VKTX) jumped back to 52-week highs above $40. The weight-loss sector has